TARSONS2024-10-012024-12-31 TARSONS2024-10-012024-12-31 TARSONS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member TARSONS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member TARSONS2024-12-31 TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue03Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue04Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue03Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue04Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults03Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults04Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults03Member TARSONS2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults04Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets03Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets04Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member TARSONS2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member TARSONS2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member TARSONS2024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member TARSONS2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities04Member TARSONS2024-12-31in-bse-fin:OneReportableSegmentLiabilities04Member TARSONS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member TARSONS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member TARSONS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member TARSONS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543399 TARSONS NOTLISTED Tarsons Products Limited Equity 2024-04-01 2025-03-31 2025-02-14 2025-01-31 INR Millions Third quarter 12:30:00 13:30:00 2025-02-14 2025-02-14 Not applicable Geographical 2024-10-01 2024-12-31 Unaudited Consolidated 956770000.00 8490000.00 965260000.00 195840000.00 111510000.00 5110000.00 163760000.00 50290000.00 174070000.00 184200000.00 884780000.00 80480000.00 0.00 80480000.00 25010000.00 2880000.00 27890000.00 0.00 52590000.00 0.00 0.00 0.00 0.00 52590000.00 35180000.00 87770000.00 0.00 0.00 0.00 0.00 106410000.00 2 0.99 0.99 0.00 0.00 0.99 0.99 1) The Statement of Consolidated Unaudited Financial Results includes results of the following entities,together referred as Group : 1)Tarsons Products Limited – Holding Company 2)Tarsons Life Science Pte. Ltd., Singapore (from November 10, 2023) – 100% - Subsidiary of Tarsons Products Limited, India 3) Nerbe plus GmbH & Co. KG, Germany (from January 1, 2024) – 100% - Subsidiary of Tarsons Life Science Pte. Ltd., Singapore 4) Nerbe R&D GmbH, Germany (from January 1, 2024) – 100% - Subsidiary of Tarsons Life Science Pte. Ltd., Singapore 2) The Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (“Consolidated Financial Results”) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on February 14, 2025. 3) The aforesaid Consolidated Unaudited Financial Results has been prepared in accordance with the Indian Accounting Standards (“Ind AS”) prescribed under Section 133 of the Companies Act, 2013, as amended (the Act ) read with relevant rules thereunder and in terms of Regulations 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). 4) During the year ended March 31, 2024, the Group has completed the acquisition of Nerbe Plus GmbH & Co KG and Nerbe R&D GmbH (collectively known as Nerbe Group ) through its wholly owned subsidiary, Tarsons Life Science Pte Ltd ( TLSPL ) incorporated in Singapore on November 10, 2023. Consequent to the acquisition, TLSPL has acquired 100% controlling stake of the Nerbe Group with effect from January 1, 2024. The Nerbe Group is involved in the business of distribution of medical and laboratory disposables in Germany. 5) During the import of machinery, certain components were damaged during transit to India. The Company has estimated the amount of loss and has filed insurance claim which is under process. The Company has recorded a total provision of INR Nil and INR 93.44 million during the quarter and nine months ended December 31, 2024 respectively in relation to damage of such components. The Company will continue pursuing the insurance claim. 6) The Group is primarily engaged in the business of manufacturing and selling of plastic laboratory products and certain scientific instruments, which represents a single business. Operating segments have been identified based on how the Board of Directors ( Chief Operating Decision Maker or CODM ) reviews and assesses the Group’s performance, which is on the basis of the different geographical areas wherein major entities within the Group operate. Geographical 2024-04-01 2024-12-31 Unaudited Consolidated 2797230000.00 121810000.00 2919040000.00 581530000.00 392060000.00 -58090000.00 485770000.00 141830000.00 424690000.00 658950000.00 2626740000.00 292300000.00 0.00 292300000.00 85750000.00 10880000.00 96630000.00 0.00 195670000.00 0.00 0.00 0.00 0.00 195670000.00 8940000.00 204610000.00 0.00 0.00 0.00 0.00 106410000.00 2 3.68 3.68 0.00 0.00 3.68 3.68 Other Expenses 184200000.00 Other Expenses 658950000.00 Germany 195260000.00 India 761510000.00 Inter-Segment Elimination 110000.00 Rest of the World 0.00 Germany 586240000.00 India 2210990000.00 Inter-Segment Elimination 340000.00 Rest of the World 0.00 956880000.00 2797570000.00 110000.00 340000.00 956770000.00 2797230000.00 Germany 19910000.00 India 287890000.00 Inter-Segment Elimination 50000.00 Rest of the World -5220000.00 Germany 65350000.00 India 800890000.00 Inter-Segment Elimination -10000.00 Rest of the World -13750000.00 302630000.00 852480000.00 50290000.00 141830000.00 171860000.00 418350000.00 80480000.00 292300000.00 Germany 1169750000.00 India 9619750000.00 Inter-Segment Elimination -1555450000.00 Rest of the World 1038040000.00 10272090000.00 0.00 10272090000.00 Germany 537210000.00 India 3252540000.00 Inter-Segment Elimination -903950000.00 Rest of the World 1159450000.00 4045250000.00 Remeasurements of post-employment benefit obligations -260000.00 Remeasurements of post-employment benefit obligations -770000.00 -260000.00 -770000.00 -70000.00 -200000.00 Foreign exchange translation reserve 35370000.00 Foreign exchange translation reserve 9510000.00 35370000.00 9510000.00 0.00 0.00